• Tomasz Mandat, Tomasz Tykocki, Henryk Koziara, Dariusz Koziorowski, Bogdan Brodacki, Rafał Rola, Wiesław Bonicki, and Paweł Nauman.
• Centrum Onkologii - Instytut, Klinika Nowotworów Układu Nerwowego, ul. Roentgena 5, 02-781 Warszawa. tomaszmandat@yahoo.com
• Neurol Neurochir Pol. 2011 Jan 1; 45 (1): 32-6.

Background And PurposeThe role of subthalamic nucleus deep brain stimulation (STN DBS) in the treatment of Parkinson disease (PD) is well established. The authors present a group of patients diagnosed with PD who were treated with STN DBS.Material And MethodsBetween 2008 and 2009, 32 female and 34 male patients with PD were treated with STN DBS. Mean age at implantation was 57 ± 12 years. PD lasted from 6 to 21 years (mean 10 years). Patients were qualified for the surgery according to the CAPSIT-PD criteria. The STN was identified with direct and indirect methods. Macrostimulation and microrecording for STN identification were used in all cases. A unilateral STN DBS system was implanted in two cases and bilateral implantation was performed among rest of the group. Outcome was assessed six months after implantation. Results : The mean reduction of UPDRS III score among 51 patients who underwent follow-up was 45% (5-89%). Reduction of levodopa consumption varied from 15 to 100%. Infection forced the authors to remove the DBS system in one case four months after implantation. Skin erosion above the internal pulse generator was noted in four cases.ConclusionsCardinal symptoms of Parkinson's disease can be safely and effectively treated with STN DBS in selected group of patients.

25 keywords...

hide…